Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-DFO-B7-H4-Ab
- Development stage
- Preclinical
- Lead developer
- National Cancer Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Administration
- Intravenous
01
Overview
89Zr-DFO-B7-H4-Ab is a zirconium-89-labeled monoclonal antibody conjugate developed for positron emission tomography (PET) imaging of B7-H4-expressing solid tumors. It consists of a mouse anti-human B7-H4 monoclonal antibody conjugated to the chelator deferoxamine (DFO) and radiolabeled with the positron emitter zirconium-89 (89Zr). B7-H4 (VTCN1) is an immune checkpoint protein overexpressed in various epithelial malignancies, including breast and ovarian cancers, while showing minimal expression in normal tissues. In preclinical studies, 89Zr-DFO-B7-H4-Ab PET imaging demonstrated high and specific tumor uptake, enabling quantitative, non-invasive visualization of B7-H4 expression levels to facilitate patient selection and treatment monitoring for B7-H4-targeted therapies.
- Other names
- [89Zr]Zr-B7-H4 Ab[89Zr]Zr-DFO-B7-H4-Ab89Zr-B7-H4 Ab89Zr-DFO-B7-H4
02
Targets
VTCN1 (V-set domain containing T cell activation inhibitor 1)
Beyond the preview
Go deeper on 89Zr-DFO-B7-H4-Ab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-DFO-B7-H4-Ab.